Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Core Insights - Orchestra BioMed announced a late-breaking presentation on the benefits of atrioventricular interval modulation (AVIM) therapy for patients with diastolic dysfunction at the THT 2025 Conference [1][2] - The retrospective analysis from the MODERATO II study showed significant improvements in echocardiographic markers of diastolic dysfunction in hypertensive patients receiving AVIM therapy [1][4] Company Overview - Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact technologies through partnerships with leading medical device companies [9] - The company's lead product candidate is AVIM therapy, aimed at treating hypertension, a major global health risk [9][11] Study Findings - The MODERATO II study involved a treatment-blinded analysis assessing the impact of 6 months of AVIM therapy on systolic blood pressure (SBP) and echocardiographic markers of diastolic dysfunction [4][7] - Among the 36 patients with sufficient echocardiographic data, 61% exhibited evidence of diastolic dysfunction [4] Clinical Data - AVIM therapy resulted in a significant reduction in ambulatory SBP by 8.3±9.7 mmHg and office SBP by 12.1±12.8 mmHg in patients with diastolic dysfunction [7] - Key measures of diastolic function improved significantly, including an increase in e' from 5.9±2.0 to 8.8±3.4 cm/sec and E/A ratio from 0.86±0.39 to 1.60±0.84 [7] Future Directions - The ongoing BACKBEAT global pivotal study aims to further evaluate the safety and efficacy of AVIM therapy in patients with uncontrolled hypertension and diastolic dysfunction [8][11] - The findings from the MODERATO II study suggest a potential new paradigm for treating hypertension and its associated risks, particularly in high-risk populations [8]